CSPC enters strategic research collaboration with AstraZeneca

CSPC Pharmaceutical Group Limited (HKEX:1093) announced a strategic research collaboration agreement with AstraZeneca to discover and develop novel oral small molecule candidates. Under the agreement, CSPC will utilize its AI-driven, dual-engine efficient drug discovery platform for targets selected by AstraZeneca, focusing on diseases across various indications. AstraZeneca will have the option to license the programs, with CSPC receiving an upfront payment of US$110 million. Additionally, CSPC is eligible for up to US$1,620 million in potential development milestone payments and up to US$3,600 million in potential sales milestone payments, alongside potential single-digit royalties on net sales. The deal underscores CSPC’s commitment to innovation and partnership in the pharmaceutical sector.